Search

everythinglearnresearchcommunity

for

Search:↓

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.

Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Baricitinib may cause low blood sugar in some patients, so careful monitoring is needed.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

JAK inhibitors show promise for treating various skin diseases.

JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.